Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: old 'n cranky who wrote (10049)	4/10/2018 2:55:45 AM
From: HardToFind	Read Replies (1) \| Respond to of 12873

Two candidates will cost twice as much as one would. On a rough scale I'd guess that's about 80% correct. If they have the same indications there would be a few economies of scale: Same tox protocol Same human clinical trial protocols Pre-IND meeting for two candidates at once Similar GLP process documentation packages And I don't want to re-read the PR but I believe that they use the plural (candidates) without specifying a number....a belief that it is two may not be safe. The company has heretofore made it known that there were two candidates (specifically referred to in the poster presentation as NV-118 and NV-121). I've heard informal statements from Dr. Seymour (which have been corroborated by another shareholder) that one is slightly more effective and one is a bit easier to make. Could there have been three or more sent off for informal tox testing? Yes...it's possible, but I'd give it less than a 10% chance that NNVC will take more than two shingles drug candidates into formal tox testing anytime soon. Then again, what's the chance anything goes into formal tox testing anytime soon? I don't know, and don't want to hazard a guess as to what sort of time frame "moving rapidly towards human clinical trials" means for this company. (I've been wrong trying to guess schedules too many times before.)